Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Adult T-cell Leukemia-lymphoma Clinical Trial

Official title:
Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma

Status Completed

Clinical Trial Summary

To evaluate the efficacy, safety and pharmacokinetic profiles of KW-0761, the anti-CC chemokine receptor 4 (CCR4) antibody, when administered weekly for 8 weeks as an intravenous infusion at a dose of 1.0 mg/kg in relapsed subjects with CCR4-positive adult T-cell leukemia-lymphoma.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00920790
Study type	Interventional
Source	Kyowa Hakko Kirin Company, Limited
Contact
Status	Completed
Phase	Phase 2
Start date	June 2009
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01724177` - A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Phase 2
Completed	`NCT01626664` - KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Phase 2
Completed	`NCT01173887` - Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15	Phase 2
Completed	`NCT01169298` - A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma	Phase 1
Recruiting	`NCT02737046` - Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma	Phase 2